Company Overview and News
Shares of streaming device maker Roku (NASDAQ:ROKU) have been red-hot for the past few months. Ever since Roku stock dropped to $30 in early April 2018 after a weak first quarter guide, the stock has proceeded to rebound all the way back to $50. That is a powerful, near 70% rally for Roku in just three months.
AMZN ROKU NFLX GOOG
After an impressive rally off its lows for Netflix (NASDAQ:NFLX), it helped lead tech out of an early rout on Tuesday. Unsurprisingly, that gave a big boost to stocks on the day. Any surprise we’re starting with Netflix as our first trade?
ULTA JNJ ROKU NFLX BB
Roku (NASDAQ:ROKU) is a very polarizing stock with big bears and big bulls on each side. The bulls call Roku the next Netflix (NASDAQ:NFLX). They think that Roku stock can and will head to $100, $200, and higher over the next several years as the over-the-top (OTT) media revolution goes global.
GPRO FB AMZN ROKU NFLX GOOG
Pivotal Systems' wildly successful launch of trading on the Australian Securities Exchange on July 2nd creates an enormous windfall for the Firsthand Technology Value Fund.
FB YELP ROKU TWTR SCTY SVVC NTNX
We’re now officially into the dog days of summer… a time of year that’s not just painfully hot outdoors, but notoriously slow for stocks. On average, the S&P 500 goes nowhere between mid-July and mid-October.
HON FB XKE DATA NBIX NYTAB NVDA SNEJF EXPE TGT HON ROKU SNE DXC.WI DXC
Shares of Roku (NASDAQ:ROKU), the California based over-the-top (OTT) television streaming platform, were on a rally mode last week. The rally was driven by bullish analyst sentiments, as Wall Street analysts see Roku gain a bigger share of the OTT television ecosystem. Here we use TipRanks data to take a closer look at what Wall Street's top analysts see in store for this volatile stock.
AMZN GOOGL ROKU AAPL NFLX GOOG
We now partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
Shares of Roku (ROKU - Free Report) soared over 7% on Tuesday one day after Oppenheimer analysts upgraded the streaming TV firm. So now let’s take a look to see if Roku stock might be worth buying with the streaming content revolution set to continue.
BLT BHP VIAB BHPBF ROKU AAPL BBL NFLX BHP BHPLF
Stocks were looking for a higher open on Tuesday, with this day being a shortened one ahead of the July 4th holiday. The prior trend of buying the dips has not worked as well in recent months as it had in prior years. Many investors have been considering how they want their investments positioned ahead of the midterm elections and also for the longer term.
MS.PRE MS.PRF MS.PRG CVS UAL MS.PRA AMZN ZFGN CAH MS VNO.PRK VNO.PRL VNO.PRM VNO AAL MS.PRI VRAY MS.PRK ROKU ALV TRI VNO.PRG VNO.PRI WFCNP DB VNO.PRICL ALB MCK VNO.WI WFC.PRL VNORP WFC.PRJ VMW WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN ELOX WFC.PRY WFC.PRX DAL WFC.PRW WFC.PRV WFC VNO.PRH WFC.WS VNO.PRF EPZM AMED MGTX SVOND ABC PEP CVX
This is the Fund's twenty-second regular quarterly report to provide updates on the Partnership's performance. The Partnership's Fund administrator, Fund Associates, LLC, is also generating monthly investment reports for each Partner, by directly and independently accessing the Fund's electronic brokerage data.
BRK.A UA EVC TGT SWK RL ROKU UAA CRUS FDX
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ROKU / Roku Inc on message board site Silicon Investor.
as of ET